Several approaches have been developed to target NETosis in preclinical cancer models such as removal of NETs using DNase I, inhibition of the enzyme peptidylarginase deiminase 4 (PAD4) through GSK484, or blockade of the CXCR1/2 axis with reparixin [3,7,16,33,50]. This evidence concerns the gene PADI4 and cancer.